Vycor Medical (VYCO) 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	14-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	VYCOR MEDICAL INC
Entity Central Index Key	1424768
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Document Type	10-Q
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		10,821,126

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current Assets
Cash	$1,285,215	$1,891,658
Trade accounts receivable, net of allowance for doubtful accounts of $6,470 and $2,721	166,046	123,815
Inventory	310,735	336,021
Prepaid expenses and other current assets	244,537	217,800
Total Current Assets	2,006,533	2,569,294
Fixed assets, net	530,383	582,434
Intangible and Other assets:
Trademarks	251,157	251,157
Patents, net of accumulated amortization	390,486	345,113
Website, net of accumulated amortization	11,770	12,576
Security deposits	46,919	53,169
Total Intangible and Other assets	700,332	662,015
TOTAL ASSETS	3,237,248	3,813,743
Current Liabilities
Accounts payable	150,008	221,703
Accrued interest	52,469	40,634
Accrued liabilities	315,876	320,927
Derivative liability	31,945	19,792
Notes payable	330,259	321,785
TOTAL CURRENT LIABILITIES	880,557	924,841
STOCKHOLDERS' EQUITY
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 243,804 and 235,560 issued and outstanding as at March 31, 2015 and December 31, 2014 respectively	24	24
Common Stock, $0.0001 par value, 25,000,000 shares authorized 10,914,396 and 10,879,899 shares issued and 10,811,062 and 10,776,565 outstanding at March 31, 2015 and December 31, 2014 respectively	1,090	1,088
Additional Paid-in Capital	24,078,553	23,903,793
Treasury Stock (103,334 shares of Common Stock as of March 31, 2015 and December 31, 2014 respectively, at cost)	-1,033	-1,033
Accumulated Deficit	-21,888,744	-21,082,118
Accumulated Other Comprehensive Income	166,801	67,148
Total Stockholders' Equity	2,356,691	2,888,902
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$3,237,248	$3,813,743

Consolidated_Balance_Sheets_Un1

Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Consolidated Balance Sheets [Abstract]
Allowance for doubtful accounts receivable	$6,470	$2,721
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	243,804	235,560
Preferred stock, shares outstanding	243,804	235,560
Common Stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, shares authorized	25,000,000	25,000,000
Common Stock, shares issued	10,914,396	10,879,899
Common Stock, shares outstanding	10,811,062	10,776,565
Treasury Stock, shares	103,334	103,334

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Statement of Operations [Abstract]
Revenue	$328,552	$358,122
Cost of Goods Sold	51,692	42,957
Gross Profit	276,860	315,165
Operating expenses:
Research and development	23,226	15,356
Depreciation and Amortization	82,649	94,096
General and administrative	779,302	1,198,252
Total Operating expenses	885,177	1,307,704
Operating loss	-608,317	-992,539
Other income (expense)
Interest expense: Related Party		-33,829
Interest expense: Other	-11,838	-14,294
Gain (loss) on foreign currency exchange	-91,872	-632
Change in fair value of derivative liability	-12,153	253,284
Total Other income (expense)	-115,863	204,529
Loss Before Provision for Income Taxes	-724,180	-788,010
Provision for Income Taxes
Net Loss	-724,180	-788,010
Preferred dividends	-82,446
Net Loss available to common shareholders	-806,626	-788,010
Comprehensive Income (Loss)
Foreign Currency Translation Adjustment	-99,653	522
Net Comprehensive Loss	($906,279)	($787,488)
Loss Per Share
Basic and diluted	($0.07)	($0.09)
Weighted Average Number of Shares Outstanding	10,845,092	8,995,082

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($724,180)	($788,010)
Adjustments to reconcile net loss to cash used in operating activities:
Amortization of intangible assets	21,521	36,906
Depreciation of fixed assets	63,794	60,337
Provision for inventory	7,580
Share based compensation expense	88,150	168,655
(Gain) loss on foreign exchange	99,653	-28,282
Change in fair value of derivative liability	12,153	-253,284
Changes in assets and liabilities:
Accounts receivable	-43,920	-76,361
Inventory	17,433	-21,446
Prepaid expenses	-23,724	-75,635
Security Deposits	6,250
Accounts payable	-69,838	-80,833
Accrued interest: Related Party		33,829
Accrued interest: Other	11,836	-129,459
Accrued liabilities	-3,564	-8,652
Other current liabilities	8,940	3,887
Cash used in operating activities	-527,916	-1,158,348
Cash flows used in investing activities:
Purchase of fixed assets	-12,497	-29,634
Purchase of website		-5,628
Acquisition of patents	-66,276	-5,361
Cash used in investing activities	-78,773	-40,623
Cash flows from financing activities:
Proceeds from issuance of Common Stock Offering		4,070,140
Net proceeds from issuance of Notes Payable: Other	33,801	28,525
Repayment of Notes Payable: Related Party		-126,519
Repayment of Notes Payable: Other	-25,328	-126,923
Cash provided by financing activities	8,473	3,845,223
Effect of exchange rate changes on cash	-8,227	29,534
Net increase (decrease) in cash	-606,443	2,675,786
Cash at beginning of period	1,891,658	31,303
Cash at end of period	1,285,215	2,707,089
Supplemental Disclosures of Cash Flow information:
Interest paid:		143,871
Preferred stock dividends satisfied in new preferred stock	$82,446

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Basis of Presentation [Abstract]
BASIS OF PRESENTATION	1. BASIS OF PRESENTATION
	The consolidated financial statements of the Company present the financial position, results of operations, and cash flows of Vycor Medical, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive financial statements have been condensed or omitted pursuant to such rules and regulations. The consolidated balance sheet as of December 31, 2014 derives from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.
	The condensed consolidated financial statements for the three months ended March 31, 2015 and 2014, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition and results of operations. The results of operations for the three months ended March 31, 2015 and 2014 are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Certain prior period amounts have been reclassified to conform to the current presentation.

Significant_Accounting_Policie

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	2. SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation
	The consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.
	Recent Accounting Pronouncements
	From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.
	Derivative Liability
	The Company accounts for the 34,723 Series A Warrants issued in connection with the Offering (all as defined in Note 5), the holders of which have not waived their anti-dilution rights (as detailed further in Note 5) in accordance with the guidance contained in ASC 815-40-15-7D, whereby under that provision, because they have anti-dilution rights, they do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classifies the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to remeasurement at each balance sheet date until exercised or until the anti-dilution provisions contained within the warrant agreements expire, and is classified in the balance sheet as a current liability. Any change in fair value of the warrant liability is recognized in the Company’s statement of operations as other income (loss).
	Software Development Costs
	The authoritative accounting guidance requires software development costs to be capitalized upon completion of the preliminary project stage. Accordingly, direct internal and external costs associated with the development of the features and functionality of the Company’s software, incurred during the application development stage, are capitalized and amortized using the straight-line method of the estimated life of five years once the software has been brought into service. Capitalized software development costs for the three months ended March 31, 2015 and 2014 were $12,497 and $29,634, respectively.
	Net Loss Per Share
	Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.
	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:
		March 31,	March 31,
		2015	2014
	Stock options outstanding	25,557	5,557
	Warrants to purchase common stock	6,011,715	5,002,217
	Debentures convertible into common stock	195,816	518,631
	Preferred shares convertible into common stock	1,148,782	14,815
	Total	7,381,870	5,541,220

Notes_Payable

Notes Payable	3 Months Ended
	Mar. 31, 2015
Notes Payable [Abstract]
NOTES PAYABLE	3. NOTES PAYABLE
	As of March 31, 2015 and December 31, 2014, Notes Payable consists of:
		31-Mar-15	31-Dec-14
	On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 400,000 shares of the Company’s common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company an adjusted conversion price of $1.80 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended to December 31, 2015.	300,000	300,000
	Insurance policy finance agreements. During the period ended March 31, 2015 the Company received proceeds from Insurance policy finance agreement of $33,801 and made repayments of $25,328. The notes are due over the next twelve months.	30,259	21,786
	Total Notes Payable:	$330,259	$321,786
	The company assesses the value of the beneficial conversion feature of its convertible debt by determining the intrinsic value of such conversion, under ASC 470, at the time of issuance. At the time of issuance of the convertible debt instruments set out above, the fair value of the stock was either the same or less than the conversion price, and so there was no value attributable to any beneficial conversion feature.

Segment_Reporting_Geographical

Segment Reporting, Geographical Information	3 Months Ended
	Mar. 31, 2015
Segment Reporting, Geographical Information [Abstract]
SEGMENT REPORTING, GEOGRAPHICAL INFORMATION	4. SEGMENT REPORTING, GEOGRAPHICAL INFORMATION
	(a) Business segments
	The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss and which includes Sight Science. Set out below are the revenues, gross profits and total assets for each segment.
			Three Months Ended March 31,
			2015		2014
	Revenue:
	Vycor Medical		$258,849		$263,711
	NovaVision		69,703		94,411
	Total Revenue		$328,552		$358,122
	Gross Profit:
	Vycor Medical		$219,051		$233,409
	NovaVision		57,809		81,756
	Total Gross Profit		$276,860		$315,165
		March 31,		December 31,
		2015		2014
	Total Assets:
	Vycor Medical	$2,116,843		$2,644,513
	NovaVision	1,120,405		1,169,230
	Total Assets	$3,237,248		$3,813,743
	(b) Geographic information
	The Company operates in two geographic segments, the United States and Europe. Set out below are the revenues, gross profits and total assets for each segment.
		Three Months Ended March 31,
		2015		2014
	Revenue:
	United States	$283,939		$293,161
	Europe	44,613		64,961
	Total Revenue	$328,552		$358,122
	Gross Profit:
	United States	$238,352		$258,241
	Europe	$38,508		$56,924
	Total Gross Profit	$276,860		$315,165
		March 31,		December 31,
		2015		2014
	Total Assets:
	United States	$2,835,655		$3,367,679
	Europe	401,593		446,064
	Total Assets	$3,237,248		$3,813,743

Equity

Equity	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
EQUITY	5. EQUITY
	Equity Issuance
	During January to March 2015, the Company issued: 2,717 shares of Common Stock (valued at $5,000) to Steven Girgenti, 2,660 shares of Common Stock (valued at $5,000) to Oscar Bronsther and 2,660 shares of Common Stock (valued at $5,000) to Lowell Rush in consideration for services provided to the Board of Directors; and 919 shares of Common Stock (valued at $1,563) to Alvaro Pascual-Leone, 1,838 shares of Common Stock (valued at $3,125) to Josef Zihl and 831 shares of Common Stock (valued at $1,563) to each of Jason Barton and Jose Romano in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board.
	During January to March 2015, in accordance with the terms the Consulting Agreement, the Company issued 8,152 shares of Common Stock (valued at $15,000) to Fountainhead.
	During the period ended March 2015, in accordance with the terms of an investor relations advisory agreement, the Company issued 13,889 shares of Common Stock (valued at $25,000) to Acorn Management Partners.
	During the period ended March 2015 Preferred D Stock, convertible into shares of Common Stock, was issued in respect of Preferred Dividends as follows: 5,745 shares of Preferred D Stock, convertible into 26,721 shares of Common Stock (valued at $57,453) to Fountainhead; 2,119 shares of Preferred D Stock, convertible into 9,856 shares of Common Stock (valued at $21,194) to Peter Zachariou; and 380 shares of Preferred D Stock, convertible into 1,767 shares of Common Stock (valued at $3,799) to Craig Kirsch.
	Warrants and Options
	The details of the outstanding warrants and options are as follows:
					Weighted
					average
		Number of			exercise price
	STOCK WARRANTS:	shares			per share
	Outstanding at December 31, 2013	1,404,599			$3.39
	Granted	5,226,120			2.61
	Exercised	-			-
	Cancelled or expired	(719,004	)		4.46
	Outstanding at December 31, 2014	5,911,715			$2.57
	Granted	100,000			2.56
	Exercised	-			-
	Cancelled or expired	-			-
	Outstanding at March 31, 2015	6,011,715			$2.57
				Weighted
				average
		Number of		exercise price
	STOCK OPTIONS:	shares		per share
	Outstanding at December 31, 2013	5,557		$20.25
	Granted	20,000		$2.00
	Exercised	-		-
	Cancelled or expired	-		-
	Outstanding at December 31, 2014	25,557		$5.97
	Granted	-		-
	Exercised	-		-
	Cancelled or expired	-		-
	Outstanding at March 31, 2015	25,557		$5.97
	As of March 31, 2015, the weighted-average remaining contractual life of outstanding warrants and options is 2.01 and 2.95 years, respectively.

ShareBased_Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2015
Share-Based Compensation [Abstract]
SHARE-BASED COMPENSATION	6. SHARE-BASED COMPENSATION
	Stock Option Plan
	The Company adopted the Vycor Medical, Inc. Employee, Director, and Consultant Stock Plan (the “Plan”) as of February 13, 2008. The Plan provides for both incentive stock options and nonqualified stock options to be granted to employees, officers, consultants, independent contractors, directors and affiliates of the Company. The board of directors establishes the terms and conditions of all stock option grants, subject to the Plan and applicable provisions of the Internal Revenue Code. Incentive stock options must be granted at an exercise price not less than the fair market value of the common stock on the grant date. The options granted to participants owning more than 10% of the Company’s outstanding voting stock must be granted at an exercise price not less than 110% of the fair market value of the common stock on the grant date. The options expire on the date determined by the board of directors, but may not extend mare than 10 years from the grant date, while incentive stock options granted to participants owning more than 10% of the Company’s outstanding voting stock expire five years from the grant date. The vesting period for employees is generally over three years. The vesting Period for non-employees is determined based on the services being provided. The maximum number of shares of stock which may be delivered under the plan shall automatically increase by a number sufficient to cause the number of shares covered by the plan to equal 10% of the total number of shares of stock then outstanding on a fully diluted basis.
	Under ASC Topic 718, the Company estimates the fair value of option awards on the date of grant using an option pricing model. The grant date fair value is recognized over the option vesting period, the period during which an employee is required to provide service in exchange for the award. No compensation cost is recognized for equity instruments for which employees do not render the requisite service. Under these standards, compensation cost for employee cost for employee stock-based awards is based on the estimated grant-date fair value and recognized over the vesting period of the applicable award on a straight-line basis. For the period ended March 31, 2015 and 2014, the Company recognized share-based compensation of $25,011 and $0, respectively, for employee stock options.
	Stock appreciation rights may be granted either on a stand alone basis or in conjunction with all or part of any other stock options granted under the plan. As of March 31, 2015 there were no awards of any stock appreciation rights.
	Non-Employee Stock Compensation
			3 months ended
			31-Mar-15
	Name	Description	$ in period
	Steven Girgenti	2,717 shares issued for services rendered to the board of directors	$5,000
	Oscar Bronsther	2,660 shares issued for services rendered to the board of directors	$5,000
	Lowell Rush	2,660 shares issued for services rendered to the board of directors	$5,000
	Alvaro Pascual-Leone	919 shares issued for services rendered to the Scientific Advisory Board	$1,563
	Jason Barton	831 shares issued for services rendered to the Scientific Advisory Board	$1,563
	Jose Romano	831 shares issued for services rendered to the Scientific Advisory Board	$1,563
	Josef Zihl	1,838 shares issued for services rendered to the Scientific Advisory Board	$3,125
	Fountainhead Capital Mgmt	8,152 shares issued in accordance with the terms of the consulting agreement	$15,000
	Acorn Management Partners	13,889 shares issued in relation to an investor advisory agreement	$20,834
	Gordon Holmes	100,000 warrants issued in relation to an investor advisory agreement	$4,492
	Total Compensation		$63,139
	Totals and Fair Values
	Aggregate stock-based compensation expense charged to operations for stock and warrants granted to the employees and non-employees for the three months ended March 31, 2015 was $88,150. As of March 31, 2015, there was $4,167 of total unrecognized compensation costs related to warrant and stock awards and non-vested options.
	Stock-based compensation expenses related to common stock, options and warrants granted to employees and non-employees are recognized as the services are received or the stock, options and warrants are earned. The common stock, options or warrants meet the criteria for equity treatment and their fair is estimated at the grant date. Expense related to common stock is recognized on a straight-line basis over the period during which services are to be received; expense related to options and warrants is recognized on a straight-line basis over the shorter of the period during which services are to be received or the life of the option or warrant. The fair value of the common stock is determined by the then-prevailing share price. The grant date fair value of the options and warrants is estimated using the Black-Scholes option pricing model on the basis of the fair value of the underlying common stock on the measurement date, using the assumptions noted in the table below. Expected volatility is based on the historical volatility of a peer group of publicly traded companies.
	The following assumptions were used in calculations of the Black-Scholes option pricing model for the three months ended March 31, 2015 and 2014:
		Three months ended March 31,
		2015	2014
	Risk-free interest rates	1.07%	0.78%
	Expected life	3 years	3 years
	Expected dividends	0%	0%
	Expected volatility	101%	75%
	Vycor Common Stock fair value	$2.00	$2.05

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Measurements [Abstract]
FAIR VALUE MEASUREMENTS	7. FAIR VALUE MEASUREMENTS
	The Company has adopted ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period. The adoption of ASC 820 did not have an impact on the Company’s financial position or results of operations.
	The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis (the 2,062,108 Series A Warrants and Placement Agent Warrants issued as part of the Units in connection with the Offering) as of March 31, 2015 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the liability, and includes situations where there is little, if any, market activity for the liability:
	Description		31-Mar-15		Level 1	Level 2	Level 3
	Warrant Liability		$31,945		$-	$-	$31,945
	The table below provides a reconciliation of the beginning and ending balances for the liabilities measured using fair significant unobservable inputs (Level 3):
	Balance at January 1, 2015	$19,792
	Change in fair value	12,153
	Balance at March 31, 2015	$31,945
	The fair value of the Series A Warrants and Placement Agent Warrants was determined using a Monte Carlo Simulation. This model requires the input of highly subjective assumptions, including the expected price volatility, which is based on the historical volatility of a peer group of publicly traded companies. Changes in the subjective input assumptions can materially affect the estimate of fair value of the warrants and the Company’s results of operations could be impacted.
	The following assumptions were used in calculations of the Monte Carlo Simulation model for the three months ended March 31, 2015 and 2014:
		Three months ended March 31,
		2015		2014
	Risk-free interest rates	0.56%		0.68-0.93%
	Expected life	1.84 years		3 years
	Expected dividends	0%		0%
	Expected volatility	93%		71-83%
	Vycor Common Stock fair value	$1.84		$1.88-2.39

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	8. COMMITMENTS AND CONTINGENCIES
	Lease
	The Company leases approximately 10,000 sq. ft located at 6401 Congress Ave., Suite 140, Boca Raton, FL 33487 from Catexor Limited Partnership for a gross rent of $14,260 plus sales tax per month. The term of the lease is 5 years and 6 months terminating July, 2017. The Company’s subsidiaries in Germany and the UK occupy properties on short term lease agreements. Rent expense for the three months ended March 31, 2015 and 2014 was $47,211 and $50,178 respectively.
	Potential German tax liability
	In June 2012 the Company's German subsidiary received a preliminary assessment for Magdeburg City trade tax of approximately €75,000 (approximately $94,000). This assessment is for the 2010 fiscal year and relates to the Company's acquisition of the assets of the former NovaVision, Inc. An initial assessment for corporate tax for the same period has been preliminarily reduced to zero. The Company has not accepted this trade tax assessment and is in discussion with the relevant tax authorities with a view to its reduction. The tax authorities have agreed to suspend the assessment pending the outcome of certain court hearings, and the Company has agreed to make limited monthly payments on account. To the extent that this assessment, a higher or a reduced amount, is ultimately confirmed by the tax authorities, the Company believes it has a very strong claim against certain professional advisors which would offset the liability in full. Accordingly, the Company has made no provision for this liability for the three months ending March 31, 2015, other than recording the monthly payments as an expense.
	Potential Patent Infringement
	The Company was made aware in 2012 that a competitor had been granted a patent for related technology, and appeared to be entering the market with products that infringe the Company’s own issued patent. Following investigation, the Company has taken steps to initiate an invalidation of the competitor’s patent and enforce its patent rights; in March 2014 the Patent Re-examination Board issued an Examination Decision invalidating all the claims of the competitor’s patent. The competitor has the right of appeal but the Company will contest any such appeal. The Company has also been made aware that a second competitor has filed a patent application for related technology and also may be producing a product that potentially infringes the Company’s patent, and is in the early stages of evaluation and has yet to determine what, if any actions to take in this instance, however as a general rule the Company intends to take all necessary action to protect its patent portfolio. As with all patent infringement actions, there is some risk that the accused infringer will not be found to infringe the claims, and an additional risk that the accused infringer will successfully challenge the validity of the asserted claims.

Consulting_and_Other_Agreement

Consulting and Other Agreements	3 Months Ended
	Mar. 31, 2015
Consulting and Other Agreements [Abstract]
CONSULTING AND OTHER AGREEMENTS	9. CONSULTING AND OTHER AGREEMENTS
	The following agreements were entered into or remained in force during the three months ended March 31, 2015:
	Under the terms of an amended Consulting Agreement between the Company and Fountainhead, Fountainhead is paid a monthly retainer of $10,000 per month, payable $5,000 in cash and $5,000 payable in Company Common Stock at the end of each quarter.
	In January 2015, the Company entered into a twelve (12) month agreement to provide financial advisory, strategic business planning and professional relations services, with Acorn Management Partners (“Acorn”). Under the terms of the Acorn Agreement, Acorn receives $8,000 in cash per month and 25,000 shares of Restricted Common Stock in the first two three month periods and $8,000 in cash per month and 75,000 shares of restricted common stock in the final two three month periods.
	In March 2015, the Company entered into a twelve (12) month agreement to provide investor relations services with Gordon Holmes. Under the terms of the agreement, Gordon Holmes received warrants to purchase 100,000 Vycor shares of Common Stock at $2.56, exercisable for a period of three years.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	10. RELATED PARTY TRANSACTIONS
	On March 31 2015, in accordance with the terms of the Consulting Agreement, the Company issued 8,152 shares of Common Stock (valued at $15,000) to Fountainhead.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	11. SUBSEQUENT EVENTS
	The Company evaluated subsequent events through the date the financial statements were issued and filed with this Form 10Q:
	Share Issuance
	During April to May 2015, the Company issued 2,660 shares of Common Stock (valued at $5,000) to Steven Girgenti, in consideration for services provided to the Board of Directors, and 925 and 1,849 shares of Common Stock respectively (valued at $1,563 and $3,125 respectively) to Alvaro Pascual-Leone and Josef Zihl in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board.
	During April 2015 the Company issued 4,630 shares of Common Stock (valued at $8,333) to Acorn Partners in accordance with the terms of the Acorn Agreement.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Significant Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
	The consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.
Derivative Liability	Derivative Liability
	The Company accounts for the 34,723 Series A Warrants issued in connection with the Offering (all as defined in Note 5), the holders of which have not waived their anti-dilution rights (as detailed further in Note 5) in accordance with the guidance contained in ASC 815-40-15-7D, whereby under that provision, because they have anti-dilution rights, they do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classifies the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to remeasurement at each balance sheet date until exercised or until the anti-dilution provisions contained within the warrant agreements expire, and is classified in the balance sheet as a current liability. Any change in fair value of the warrant liability is recognized in the Company’s statement of operations as other income (loss).
Software Development Costs	Software Development Costs
	The authoritative accounting guidance requires software development costs to be capitalized upon completion of the preliminary project stage. Accordingly, direct internal and external costs associated with the development of the features and functionality of the Company’s software, incurred during the application development stage, are capitalized and amortized using the straight-line method of the estimated life of five years once the software has been brought into service. Capitalized software development costs for the three months ended March 31, 2015 and 2014 were $12,497 and $29,634, respectively.
Net Loss Per Share	Net Loss Per Share
	Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.
	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:
		March 31,	March 31,
		2015	2014
	Stock options outstanding	25,557	5,557
	Warrants to purchase common stock	6,011,715	5,002,217
	Debentures convertible into common stock	195,816	518,631
	Preferred shares convertible into common stock	1,148,782	14,815
	Total	7,381,870	5,541,220

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Significant Accounting Policies [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share
		March 31,	March 31,
		2015	2014
	Stock options outstanding	25,557	5,557
	Warrants to purchase common stock	6,011,715	5,002,217
	Debentures convertible into common stock	195,816	518,631
	Preferred shares convertible into common stock	1,148,782	14,815
	Total	7,381,870	5,541,220

Notes_Payable_Tables

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2015
Notes Payable [Abstract]
Components of notes payable
		31-Mar-15	31-Dec-14
	On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 400,000 shares of the Company’s common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company an adjusted conversion price of $1.80 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended to December 31, 2015.	300,000	300,000
	Insurance policy finance agreements. During the period ended March 31, 2015 the Company received proceeds from Insurance policy finance agreement of $33,801 and made repayments of $25,328. The notes are due over the next twelve months.	30,259	21,786
	Total Notes Payable:	$330,259	$321,786

Segment_Reporting_Geographical1

Segment Reporting, Geographical Information (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting, Geographical Information [Abstract]
Schedule of business segments information			Three Months Ended March 31,
			2015		2014
	Revenue:
	Vycor Medical		$258,849		$263,711
	NovaVision		69,703		94,411
	Total Revenue		$328,552		$358,122
	Gross Profit:
	Vycor Medical		$219,051		$233,409
	NovaVision		57,809		81,756
	Total Gross Profit		$276,860		$315,165
		March 31,		December 31,
		2015		2014
	Total Assets:
	Vycor Medical	$2,116,843		$2,644,513
	NovaVision	1,120,405		1,169,230
	Total Assets	$3,237,248		$3,813,743
Summary of geographic information		Three Months Ended March 31,
		2015		2014
	Revenue:
	United States	$283,939		$293,161
	Europe	44,613		64,961
	Total Revenue	$328,552		$358,122
	Gross Profit:
	United States	$238,352		$258,241
	Europe	$38,508		$56,924
	Total Gross Profit	$276,860		$315,165
		March 31,		December 31,
		2015		2014
	Total Assets:
	United States	$2,835,655		$3,367,679
	Europe	401,593		446,064
	Total Assets	$3,237,248		$3,813,743

Equity_Tables

Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Derivative [Line Items]
Summary of outstanding warrants and options				Weighted
				average
		Number of		exercise price
	STOCK OPTIONS:	shares		per share
	Outstanding at December 31, 2013	5,557		$20.25
	Granted	20,000		$2.00
	Exercised	-		-
	Cancelled or expired	-		-
	Outstanding at December 31, 2014	25,557		$5.97
	Granted	-		-
	Exercised	-		-
	Cancelled or expired	-		-
	Outstanding at March 31, 2015	25,557		$5.97
Stock Warrants [Member]
Derivative [Line Items]
Summary of outstanding warrants and options					Weighted
					average
		Number of			exercise price
	STOCK WARRANTS:	shares			per share
	Outstanding at December 31, 2013	1,404,599			$3.39
	Granted	5,226,120			2.61
	Exercised	-			-
	Cancelled or expired	(719,004	)		4.46
	Outstanding at December 31, 2014	5,911,715			$2.57
	Granted	100,000			2.56
	Exercised	-			-
	Cancelled or expired	-			-
	Outstanding at March 31, 2015	6,011,715			$2.57

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Share-Based Compensation [Abstract]
Schedule of non-employee stock compensation			3 months ended
			31-Mar-15
	Name	Description	$ in period
	Steven Girgenti	2,717 shares issued for services rendered to the board of directors	$5,000
	Oscar Bronsther	2,660 shares issued for services rendered to the board of directors	$5,000
	Lowell Rush	2,660 shares issued for services rendered to the board of directors	$5,000
	Alvaro Pascual-Leone	919 shares issued for services rendered to the Scientific Advisory Board	$1,563
	Jason Barton	831 shares issued for services rendered to the Scientific Advisory Board	$1,563
	Jose Romano	831 shares issued for services rendered to the Scientific Advisory Board	$1,563
	Josef Zihl	1,838 shares issued for services rendered to the Scientific Advisory Board	$3,125
	Fountainhead Capital Mgmt	8,152 shares issued in accordance with the terms of the consulting agreement	$15,000
	Acorn Management Partners	13,889 shares issued in relation to an investor advisory agreement	$20,834
	Gordon Holmes	100,000 warrants issued in relation to an investor advisory agreement	$4,492
	Total Compensation		$63,139
Schedule of assumptions used in calculations of the Black-Scholes option pricing model		Three months ended March 31,
		2015	2014
	Risk-free interest rates	1.07%	0.78%
	Expected life	3 years	3 years
	Expected dividends	0%	0%
	Expected volatility	101%	75%
	Vycor Common Stock fair value	$2.00	$2.05

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Measurements [Abstract]
Schedule liabilities measured at fair value on a recurring basis	Description		31-Mar-15		Level 1	Level 2	Level 3
	Warrant Liability		$31,945		$-	$-	$31,945
Schedule of liabilities measured using fair significant unobservable inputs (Level 3)
	Balance at January 1, 2015	$19,792
	Change in fair value	12,153
	Balance at March 31, 2015	$31,945
Schedule of fair value assumptions used in calculation of the Monte Carlo Simulation model		Three months ended March 31,
		2015		2014
	Risk-free interest rates	0.56%		0.68-0.93%
	Expected life	1.84 years		3 years
	Expected dividends	0%		0%
	Expected volatility	93%		71-83%
	Vycor Common Stock fair value	$1.84		$1.88-2.39

Significant_Accounting_Policie3

Significant Accounting Policies (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Potential shares of common stock that are not included in the calculation of diluted net loss per share
Potential shares of common stock that are not included in the calculation of diluted net loss per share	7,381,870	5,541,220
Stock options outstanding [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share
Potential shares of common stock that are not included in the calculation of diluted net loss per share	25,557	5,557
Warrants to purchase common stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share
Potential shares of common stock that are not included in the calculation of diluted net loss per share	6,011,715	5,002,217
Debentures convertible into common stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share
Potential shares of common stock that are not included in the calculation of diluted net loss per share	195,816	518,631
Preferred shares convertible into common stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share
Potential shares of common stock that are not included in the calculation of diluted net loss per share	1,148,782	14,815

Significant_Accounting_Policie4

Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Significant Accounting Policies (Textual)
Estimated useful life of software	5 years
Software and Software Development Costs [Member]
Significant Accounting Policies (Textual)
Capitalized software development cost additions	$12,497	$29,634

Notes_Payable_Details

Notes Payable (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Components of notes payable
Total Related Party Notes Payable:	$330,259	$321,786
Term notes issued on March 25, 2011[Member]
Components of notes payable
Total Related Party Notes Payable:	300,000	300,000
Insurance policy finance agreements [Member]
Components of notes payable
Total Related Party Notes Payable:	$30,259	$21,786

Notes_Payable_Details_Textual

Notes Payable (Details Textual) (USD $)	0 Months Ended
	Mar. 25, 2011	Jun. 25, 2011	Mar. 31, 2015
Term notes issued on March 25, 2011[Member]
Notes Payable (Textual)
Term notes payables	$300,000
Interest rate on term notes	16.00%
Number of common stock purchased by issuance of warrants	400,000
Exercise price of warrants	$4.50	$1.80
Period of warrants	3 years
Debt instruments, original maturity date	25-Jun-11
Debt instruments, extended maturity date description	The due date for this note has been extended to December 31, 2015
Insurance policy finance agreements [Member]
Notes Payable (Textual)
Issuance of convertible debentures			33,801
Repayment of convertible debt			$25,328

Segment_Reporting_Geographical2

Segment Reporting, Geographical Information (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Revenue:
Total Revenue	$328,552	$358,122
Gross Profit:
Total Gross Profit	276,860	315,165
Total Assets:
Total Assets	3,237,248		3,813,743
Vycor Medical [Member]
Revenue:
Total Revenue	258,849	263,711
Gross Profit:
Total Gross Profit	219,051	233,409
Total Assets:
Total Assets	2,116,843		2,644,513
NovaVision [Member]
Revenue:
Total Revenue	69,703	94,411
Gross Profit:
Total Gross Profit	57,809	81,756
Total Assets:
Total Assets	$1,120,405		$1,169,230

Segment_Reporting_Geographical3

Segment Reporting, Geographical Information (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Revenue:
Total Revenue	$328,552	$358,122
Gross Profit:
Total Gross Profit	276,860	315,165
Total Assets:
Total Assets	3,237,248		3,813,743
United States [Member]
Revenue:
Total Revenue	283,939	293,161
Gross Profit:
Total Gross Profit	238,352	258,241
Total Assets:
Total Assets	2,835,655		3,367,679
Europe [Member]
Revenue:
Total Revenue	44,613	64,961
Gross Profit:
Total Gross Profit	38,508	56,924
Total Assets:
Total Assets	$401,593		$446,064

Segment_Reporting_Geographical4

Segment Reporting, Geographical Information (Details Textual)	3 Months Ended
	Mar. 31, 2015
	Segment
Segment Reporting, Geographical Information (Textual)
Number of business segments	2
Number of geographic segments	2

Equity_Details

Equity (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Stock options [Member]
Details of the outstanding rights, options and warrants and value of such rights, options and warrants
Options Outstanding, Beginning Balance	25,557	5,557
Number of shares, Granted		20,000
Number of shares, Exercised
Number of shares, Cancelled or expired
Options Outstanding, Ending Balance	25,557	25,557
Weighted average exercise price per share, Outstanding, Beginning Balance	$5.97	$20.25
Weighted average exercise price per share, Granted		$2
Weighted average exercise price per share, Exercised
Weighted average exercise price per share, Cancelled or expired
Weighted average exercise price per share, Outstanding, Ending balance	$5.97	$5.97
Stock Warrants [Member]
Details of the outstanding rights, options and warrants and value of such rights, options and warrants
Options Outstanding, Beginning Balance	5,911,715	1,404,599
Number of shares, Granted	100,000	5,226,120
Number of shares, Exercised
Number of shares, Cancelled or expired		719,004
Options Outstanding, Ending Balance	6,011,715	5,911,715
Weighted average exercise price per share, Outstanding, Beginning Balance	$2.57	$3.39
Weighted average exercise price per share, Granted	$2.56	$2.61
Weighted average exercise price per share, Exercised
Weighted average exercise price per share, Cancelled or expired		$4.46
Weighted average exercise price per share, Outstanding, Ending balance	$2.57	$2.57

Equity_Details_Textual

Equity (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015
Equity (Textual)
Common stock issued value	$63,139
Steven Girgenti [Member]
Equity (Textual)
Common stock issued shares	2,717
Common stock issued value	5,000
Dr Oscar Bronsther [Member]
Equity (Textual)
Common stock issued shares	2,660
Common stock issued value	5,000
Lowell Rush [Member]
Equity (Textual)
Common stock issued shares	2,660
Common stock issued value	5,000
Alvaro Pascual - Leone [Member]
Equity (Textual)
Common stock issued shares	919
Common stock issued value	1,563
Josef Zihl [Member]
Equity (Textual)
Common stock issued shares	1,838
Common stock issued value	3,125
Jason Barton [Member]
Equity (Textual)
Common stock issued shares	831
Common stock issued value	1,563
Jose Romano [Member]
Equity (Textual)
Common stock issued shares	831
Common stock issued value	1,563
Fountainhead Capital Partners Limited [Member]
Equity (Textual)
Common stock issued shares	8,152
Common stock issued value	15,000
Acorn Management Partners [Member]
Equity (Textual)
Common stock issued shares	13,889
Common stock issued value	25,000
Series D Preferred Stock [Member] | Fountainhead Capital Partners Limited [Member]
Equity (Textual)
Convertible preferred stock, Shares issued upon conversion	5,745
Shares converted into common stock, Shares	26,721
Shares converted into common stock, Amount	57,453
Series D Preferred Stock [Member] | Craig Kirsch [Member]
Equity (Textual)
Convertible preferred stock, Shares issued upon conversion	380
Shares converted into common stock, Shares	1,767
Shares converted into common stock, Amount	3,799
Series D Preferred Stock [Member] | Peter Zachariou [Member]
Equity (Textual)
Convertible preferred stock, Shares issued upon conversion	2,119
Shares converted into common stock, Shares	9,856
Shares converted into common stock, Amount	$21,194

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	$63,139
Steven Girgenti [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	5,000
Dr Oscar Bronsther [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	5,000
Lowell Rush [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	5,000
Alvaro Pascual - Leone [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	1,563
Jason Barton [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	1,563
Jose Romano [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	1,563
Josef Zihl [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	3,125
Fountainhead Capital Partners Limited [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	15,000
Acorn Management Partners [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	25,000
Gordon Holmes [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock issued value	$4,492

ShareBased_Compensation_Detail1

Share-Based Compensation (Details 1) (Stock options [Member], USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Stock options [Member]
Options and warrants expensed
Risk-free interest rates	1.07%	0.78%
Expected life	3 years	3 years
Expected dividends	0.00%	0.00%
Expected volatility	101.00%	75.00%
Vycor Common Stock fair value	$2	$2.05

ShareBased_Compensation_Detail2

Share-Based Compensation (Details Textual) (USD $)	0 Months Ended	3 Months Ended
	Feb. 13, 2008	Mar. 31, 2015	Mar. 31, 2014
Share-Based Compensation (Textual)
Share based compensation expense		$88,150	$168,655
Total unrecognized compensation costs		4,167
Steven Girgenti [Member]
Share-Based Compensation (Textual)
Common stock issued shares		2,717
Dr Oscar Bronsther [Member]
Share-Based Compensation (Textual)
Common stock issued shares		2,660
Lowell Rush [Member]
Share-Based Compensation (Textual)
Common stock issued shares		2,660
Alvaro Pascual - Leone [Member]
Share-Based Compensation (Textual)
Common stock issued shares		919
Jason Barton [Member]
Share-Based Compensation (Textual)
Common stock issued shares		831
Jose Romano [Member]
Share-Based Compensation (Textual)
Common stock issued shares		831
Josef Zihl [Member]
Share-Based Compensation (Textual)
Common stock issued shares		1,838
Fountainhead Capital Partners Limited [Member]
Share-Based Compensation (Textual)
Common stock issued shares		8,152
Acorn Management Partners [Member]
Share-Based Compensation (Textual)
Common stock issued shares		13,889
Gordon Holmes [Member]
Share-Based Compensation (Textual)
Common stock issued shares		100,000
Stock Option Plan [Member]
Share-Based Compensation (Textual)
Ownership percentage of outstanding voting stock for the options to be granted	More than 10%.
Exercise price of options granted	Not less than 110% of the fair market value of the common stock on the grant date.
Option expired period determined by the board of directors	Not extend mare than 10 years from the grant date.
Outstanding voting stock expire from grant date	10 years
Vesting period for employees	3 years
Percentage of number of shares covered by plan	10.00%
Share-based compensation		$25,011	$0

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrant Liability	$31,945	$19,792
Level 1 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrant Liability
Level 2 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrant Liability
Level 3 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrant Liability	$31,945	$19,792

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Balance at January 31, 2015		$19,792
Balance at March 31, 2015	31,945	19,792
Level 3 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Balance at January 31, 2015	19,792
Change in fair value during period	12,153
Balance at March 31, 2015	$31,945

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 2) (Warrant [Member], USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Warrant [Member]
Fair Value Assumptions [Abstract]
Risk-free interest rates	0.56%
Risk-free interest rates, minimum		0.68%
Risk-free interest rates, maximum		0.93%
Expected life	1 year 10 months 2 days	3 years
Expected dividends	0.00%	0.00%
Expected volatility	93.00%
Expected volatility, minimum		71.00%
Expected volatility, maximum		83.00%
Vycor common stock fair value	$1.84
Vycor common stock fair value minimum		$1.88
Vycor common stock fair value maximum		$2.39

Fair_Value_Measurements_Detail3

Fair Value Measurements (Details Textual) (Fair Value, Measurements, Recurring [Member])	3 Months Ended
	Mar. 31, 2015
Fair Value, Measurements, Recurring [Member]
Fair Value Measurements (Textual)
Issuance of series A warrants and placement agent warrants shares	2,062,108

Commitments_and_Contingencies_

Commitments and Contingencies (Details)	1 Months Ended		3 Months Ended
	Jun. 30, 2012	Jun. 30, 2012	Mar. 31, 2015	Mar. 31, 2014
	USD ($)	EUR (€)	USD ($)	USD ($)
			sqft
Commitments and Contingencies (Textual)
Area of leased building (sq. ft)			10,000
Rent expenses plus sales tax (per month)			$14,260
Term of lease			5 years 6 months
Lease expiration date			31-Jul-17
Approximate preliminary assessed trade tax	94,000	75,000
Rent expense			$47,211	$50,178

Consulting_and_Other_Agreement1

Consulting and Other Agreements (Details) (USD $)	1 Months Ended	3 Months Ended
	Jan. 31, 2015	Mar. 31, 2015
Fountainhead [Member]
Consulting and Other Agreements (Textual)
Maximum cash payment for consulting services (monthly)		$10,000
Consulting fees paid by cash		5,000
Consulting fees payable through common stock		5,000
Acorn Agreement [Member] | Restricted Stock [Member]
Consulting and Other Agreements (Textual)
Restricted shares of common stock issuable under the agreement	25,000	75,000
Restricted shares of common stock issuable under the agreement, Value	$8,000	$8,000
Gordon Holmes [Member]
Consulting and Other Agreements (Textual)
Warrants to purchase common stock		100,000
Exercise price of warrants		$2.56

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Related Party Transactions (Textual)
Common stock issued value	$63,139
Fountainhead [Member]
Related Party Transactions (Textual)
Common stock issued shares	8,152
Common stock issued value	$15,000

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	3 Months Ended	2 Months Ended	1 Months Ended
	Mar. 31, 2015	31-May-15	Apr. 30, 2015
Subsequent Events (Textual)
Common stock issued in consideration for services	$63,139
Subsequent Event [Member] | Steven Girgenti [Member]
Subsequent Events (Textual)
Common stock issued in consideration for services		5,000
Common stock issued in consideration for services, Shares		2,660
Subsequent Event [Member] | Alvaro Pasual Leone [Member]
Subsequent Events (Textual)
Common stock issued in consideration for services		1,563
Common stock issued in consideration for services, Shares		925
Subsequent Event [Member] | Josef Zihl [Member]
Subsequent Events (Textual)
Common stock issued in consideration for services		3,125
Common stock issued in consideration for services, Shares		1,849
Subsequent Event [Member] | Acorn Management Partners [Member]
Subsequent Events (Textual)
Common stock issued in consideration for services			$8,333
Common stock issued in consideration for services, Shares			4,630